Stock Financial Ratios

APHB / Ampliphi Biosciences Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.31
Volume92,300.00
Market Cap ($M)5.02
Enterprise Value ($M)4.43
Book Value ($M)9.72
Book Value / Share0.59
Price / Book1.25
NCAV ($M)1.35
NCAV / Share1.56
Price / NCAV2.63
Income Statement (mra) ($M)
Revenue0.00
EBITDA-23.38
Net Income-18.84
Balance Sheet (mrq) ($M)
Cash & Equivalents7.72
Cash / Share0.47
Assets0.00
Liabilities4.02
Quick Ratio2.49
Current Ratio2.49
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.94
Return on Assets (ROA)-1.05
Return on Equity (ROE)-1.94
Identifiers and Descriptors
CUSIP03211P202
Central Index Key (CIK)921114
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Other Related CUSIPS
03211P103
03211P301
Share Statistics
Common Stock Shares Outstanding16,488,120
Temporary Equity Shares Outstanding0
Common Shares Outstanding16,488,120
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Retained Earnings Per Share0.00
Liabilities And Stock Equity Per Share0.00
Assets Other Non Current Per Share0.00
Equity Per Share0.59
Intangibles Per Share0.00
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Liabilities Current Per Share0.00
Assets Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Assets Current Per Share0.48
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Cash And Equivalents Per Share0.47
Cash Per Share0.47
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Minority Interest Per Share0.00
Liabilities Per Share0.24
Inventory Work In Progress Per Share0.00
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Debt Per Share0.00
Inventory Per Share0.00

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related News Stories

Biotech Forum Daily Digest: A Volatile Opening To 2018

2018-01-04 seekingalpha
Volatility seems to have increased early in 2018 for the biotech sector.  Strong rallies Tuesday and Wednesday have been followed by some program trading declines today. (132-2)

BRIEF-AmpliPhi Biosciences Says Engaged Ladenburg Thalmann & Co To Review Strategic Alternatives

2017-12-14 reuters
* AMPLIPHI BIOSCIENCES - ENGAGED LADENBURG THALMANN & CO. INC. TO REVIEW STRATEGIC ALTERNATIVES Source text for Eikon: Further company coverage: (16-1)

Enlisting Viruses as Allies to Fight ‘Superbugs’ - Bloomberg

2017-11-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (18-2)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-13)

CUSIP: 03211P202